Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Xtant Medical Holdings, Inc.AMEX: XTNT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $14.46M fell 22.8% year over year, behind the -7.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +25.4% a year.
Context
- Selling, general & admin amounted to 55.9% of revenue in FY2025, down 10.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $64.13M (-14.4%) for the fiscal year ending Dec 2026, a slowdown from the -3.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.46M-20.7% QoQ
- Last fiscal yearDec 2025
- $74.89M-3.9% YoY
- LTMMar 2026
- $70.61M-7.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 74.89M USD
- Year-over-year change
- -3.9%
- 4-year CAGR
- +20.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.89M | -3.9% |
| FY2024 | 2024-12-31 | 77.91M | +21.2% |
| FY2023 | 2023-12-31 | 64.29M | +69.3% |
| FY2022 | 2022-12-31 | 37.98M | +7.1% |
| FY2021 | 2021-12-31 | 35.47M | — |
Selling, General & Admin vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 selling, general & admin of $70.61M is the 3rd highest of the 8 companies compared; the peer median is $31.78M.
- Its year-over-year change of -7.6% is the 6th highest of 8, against a peer median of +9.5%.
- Selling, general & admin amounts to 57.9% of revenue for XTNT, versus a peer median of 108.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.08B | +51937.5% | +914.5% | 391112.6% | |
| LTM Mar 2026 | $78.19M | -14.1% | +20.9% | 108.1% | |
| LTM Mar 2026 | $70.61M | -7.6% | +25.4% | 57.9% | |
| LTM Mar 2026 | $37.26M | +7.2% | -5.9% | 108.4% | |
| LTM Mar 2026 | $31.78M | -9.7% | -9.1% | 56.8% | |
| LTM Mar 2026 | $21.42M | +168.1% | — | 20.3% | |
| LTM Mar 2026 | $9.52M | +9.5% | +20.6% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $5.71M | +24.9% | +91.9% | — |
| Peer median (excluding XTNT) | $31.78M | +9.5% | +20.8% | 108.1% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.26M | 57.97M | 91.3M | 117.27M | 133.93M |
| Cost of Revenue | 22.77M | 25.83M | 35.84M | 49.05M | 49.65M |
| Gross Profit | 32.49M | 32.14M | 55.47M | 68.22M | 84.27M |
| Gross Margin | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Research & Development | 870K | 915K | 1.34M | 2.39M | 2.1M |
| Selling, General & Admin | 35.47M | 37.98M | 64.29M | 77.91M | 74.89M |
| Operating Expenses | 36.34M | 38.89M | 65.63M | 80.29M | 76.99M |
| Depreciation & Amortization | 1.34M | 1.3M | 3.17M | 4.22M | 5.22M |
| EBITDA | (2.51M) | (5.43M) | 5.08M | (7.88M) | 15.9M |
| EBITDA Margin | -4.5% | -9.4% | 5.6% | -6.7% | 11.9% |
| Operating Income | (3.85M) | (6.76M) | (10.16M) | (12.07M) | 7.28M |
| Operating Margin | -7.0% | -11.7% | -11.1% | -10.3% | 5.4% |
| Interest Income | 0 | 31K | 149K | 0 | 94K |
| Interest Expense | 995K | 1.69M | 2.94M | 4.16M | 3.67M |
| Other Income / Expenses | (995K) | (1.66M) | 9.12M | (4.19M) | (283K) |
| Income Before Tax | (4.85M) | (8.42M) | (1.04M) | (16.26M) | 7M |
| Pre-Tax Margin | -8.8% | -14.5% | -1.1% | -13.9% | 5.2% |
| Income Tax Expense | 0 | 69K | (1.7M) | 187K | 2.03M |
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Net Margin | -8.8% | -14.6% | 0.7% | -14.0% | 3.7% |
| EPS (Basic) | (0.06) | (0.09) | 0.01 | (0.12) | 0.04 |
| EPS (Diluted) | (0.06) | (0.09) | 0.01 | (0.12) | 0.03 |
| Weighted Avg Shares | 85.46M | 94.09M | 119.09M | 133.67M | 139.53M |
| Weighted Avg Shares (Diluted) | 85.46M | 94.09M | 126.79M | 133.67M | 150.04M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.